Clinical trials: Differentiated Thyroid Carcinoma
Refractory Differentiated Thyroid Gland Carcinoma
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which…
- Trial name
- NCT06475989
- Testing
- Biospecimen Collection, Cabozantinib, Computed Tomography
- Where
- 307 sites in United States
- Volunteers
- 264 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Anaplastic Thyroid Cancer, Thyroid Cancer
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
This research study is a phase I/II study of MLN0128 in metastatic anaplastic thyroid cancer(ATC) and incurably poorly differentiated or radioidodine refractory differentiated thyroid cancer (DTC).
- Conditions
- Anaplastic Thyroid Cancer, Thyroid Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT02244463
- Testing
- MLN0128
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- Dana-Farber Cancer Institute
Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
This phase II trial studies the effect of selpercatinib given before surgery in treating patients with thyroid cancer whose tumors have RET alterations (changes in the genetic material [deoxyribonucleic acid (DNA)]).
- Conditions
- Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Thyroid Gland Anaplastic Carcinoma
- Trial name
- NCT04759911
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Selpercatinib
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Differentiated Thyroid Cancer
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid…
- Trial name
- NCT03690388
- Testing
- Cabozantinib
- Where
- 164 sites in United States, Argentina and 23 more
- Volunteers
- 187 people
- Sponsor
- Exelixis
Thyroid Cancer
Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer
The purpose of this Phase II single-arm study is to evaluate the efficacy of Radium-223 in treating bone lesions from differentiated thyroid cancer that are I-131 refractory.
- Trial name
- RAD-THYR (NCT02390934)
- Testing
- Radium 223
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Tumors, Solid Malignant Tumors
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid…
- Conditions
- Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC)
- Trial name
- NCT02432274
- Testing
- Lenvatinib, Ifosfamide, Etoposide
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 117 people
- Sponsor
- Eisai Limited
Follicular Thyroid Cancer, Insular Thyroid Cancer
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
This randomized phase II trial studies how well dabrafenib works with or without trametinib in treating patients with recurrent thyroid cancer.
- Conditions
- Follicular Thyroid Cancer, Insular Thyroid Cancer, Papillary Thyroid Cancer, Recurrent Thyroid Cancer
- Trial name
- NCT01723202
- Testing
- dabrafenib, trametinib
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Bhavana Konda
Thyroid Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the progression free survival, overall response rate (ORR) and safety of participants treated with lenvatinib 24 mg by continuous once…
- Trial name
- SELECT (NCT01321554)
- Testing
- Lenvatinib
- Where
- 155 sites in United States, Argentina and 21 more
- Volunteers
- 392 people
- Sponsor
- Eisai Inc.
Differentiated Thyroid Cancer
Empirical Radioactive Iodine Therapy in DTC
The aim of the study is assessment the efficacy of empiric RAI therapy in DTC patients with elevated thyroglobulin levels and negative iodine scintigraphy.
- Trial name
- NCT07453225
- Testing
- Radioactive Iodine Therapy
- Volunteers
- 100 people
- Sponsor
- Assiut University
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
This phase II trial studies how well lenvatinib and pembrolizumab work in treating patients with anaplastic thyroid cancer that is stage IVB and has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed…
- Conditions
- Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8
- Trial name
- NCT04171622
- Testing
- Lenvatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer, Renal Cell Carcinoma (RCC)
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to…
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)
- Trial name
- NCT07620574
- Testing
- Cabozantinib, Zanzalintinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Exelixis
Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
This phase II trial is studying how well tanespimycin works in treating patients with inoperable locoregionally advanced or metastatic thyroid cancer.
- Conditions
- Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer, Thyroid Gland Medullary Carcinoma
- Trial name
- NCT00118248
- Testing
- tanespimycin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Cancer, Melanoma
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
This is a pilot study designed to evaluate the cutaneous effect of systemic inhibition of the tyrosine kinase pathway in the presence or absence of solar simulated light exposure.
- Conditions
- Metastatic Cancer, Melanoma, Colon Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT03176485
- Testing
- Solar Simulator
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Arizona
Thyroid Cancer, Thyroid Cancer, Medullary
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
Participants will have been diagnosed with advanced progressive thyroid cancer and are about to start treatment with a tyrosine kinase inhibitor (TKI).
- Conditions
- Thyroid Cancer, Thyroid Cancer, Medullary, Differentiated Thyroid Cancer, Papillary Thyroid Cancer
- Trial name
- NCT03630120
- Testing
- Lenvatinib, Sorafenib, Cabozantinib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Radioactive Iodine-refractory Differentiated Thyroid Cancer
Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer
This is a single arm, open-label, non-randomized and single-center phase II clinical study, to evaluate the safety, tolerance, and efficacy of Camrelizumab in combination with Apatinib in patients with Radioactive…
- Trial name
- NCT04560127
- Testing
- Camrelizumab combination with Apatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Thyroid, Metastasis
Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers
The purpose of this study is to determine Safety and Efficacy of Radioactive Iodine (RAI) Treatment of Metastatic and Advanced Differentiated Thyroid Cancers by Pretreatment With Apatinib for the Neoadjuvant Regimen
- Conditions
- Thyroid, Metastasis, Apatinib
- Trial name
- APT-01 (NCT04180007)
- Testing
- Apatinib
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
This phase II trial studies how well giving sunitinib malate works in treating patients with iodine-refractory recurrent or metastatic thyroid cancer.
- Conditions
- Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer
- Trial name
- NCT00519896
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Washington
Bone Sarcoma, Dedifferentiated Chondrosarcoma
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer…
- Conditions
- Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone, Malignancy in Giant Cell Tumor of Bone
- Trial name
- NCT03449108
- Testing
- Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Thyroid Cancer
Study of External Beam Radiotherapy to Thyroid Carcinoma
The primary objective of this study is to estimate the 5 year locoregional control rate after External Beam Radiotherapy (EBRT) in the patient with locally advanced differentiated thyroid cancer.
- Trial name
- NCT01173289
- Testing
- External Beam Radiotherapy
- Where
- South Korea
- Volunteers
- 62 people
- Sponsor
- National Cancer Center, Korea
Thyroid Cancer
Comparison of I-124 and I-131 Radiopharmacokinetics in DTC Patients With Thyroid Hormone Withdrawal
This research study is to compare the radiopharmacokinetics of I-124 to the radiopharmacokinetics of I-131 in patients who have well-differentiated thyroid cancer after thyroid hormone withdrawal.
- Trial name
- NCT02947399
- Testing
- Radioactive Iodine 124
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Medstar Health Research Institute